Saturday 17 October 2026 Export CTMX’s income statement to Excel — free account

CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.4%, EPS fell 7,400.0% and free cash flow fell 14.5%, each against the same quarter a year earlier.

2.27 0.14 −5.81%

Follow CTMX

Alert me

Market cap: $525.1M
P/E: 0.0×
Fwd P/E: −6.9×
Dividend yield: —
F-score: 2/9
Altman Z: 0.92
Beneish M: −1.09
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.69

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	4	—	—	1	—	—	—	—

Insider Ownership 19.37%

Capital & Financial Ratios $m

Market Cap 525.14

Revenue 18.30

Net Income (79.65)

Free Cash Flow (82.41)

Net Debt (331.20)

Current Ratio 9.36

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (6.86)

P/S ratio 27.16

P/B ratio 1.65

Past 5Y EPS Growth —

This Y EPS Growth (154.28%)

Next Y EPS Growth (20.00%)

Next Y revenue growth (67.15%)

Next 5Y EPS Growth (0.90%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 88.09%

10-year low 10-year high

P/B against its own 10 years 4.35%

10-year low 10-year high

EV/Sales against its own 10 years 71.00%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	175	101	137	331
Receivables	3	3	2	37
Inventory	—	—	—	—
Other	—	—	—	—
	183	107	144	373

	2023	2024	2025	Q'26
Payables	1	1	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	156	86	47	40

Compound Annual Growth %

	10y	5y	3y
Sales	25.74%	(5.36%)	12.75%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(2.39%)	14.73%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	10	1	—	—	—
’25	51	19	6	1	76
’24	41	25	33	38	138
’23	23	25	26	27	101
’22	9	13	11	20	53
’21	16	16	18	(13)	37
’20	50	17	18	16	100

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(18)	—	—	—
’25	(21)	(16)	(16)	(23)	(76)
’24	(26)	(20)	(21)	(20)	(86)
’23	9	(25)	(18)	(22)	(56)
’22	(41)	(34)	(34)	(1)	(111)
’21	(30)	(28)	(30)	(31)	(119)
’20	(50)	97	(25)	(17)	5

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(18)	—	—	—
’25	(21)	(16)	(15)	(23)	(76)
’24	(26)	(20)	(21)	(20)	(87)
’23	9	(26)	(18)	(22)	(57)
’22	(42)	(35)	(34)	(2)	(113)
’21	(31)	(28)	(30)	(31)	(121)
’20	(51)	97	(25)	(18)	3

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.10)	(0.09)	—	—	—
’25	0.27	0.00	(0.09)	(0.22)	(0.15)
’24	0.17	(0.08)	0.07	0.22	0.38
’23	(0.05)	(0.02)	0.04	0.01	(0.01)
’22	(0.37)	(0.37)	(0.35)	(0.13)	(1.51)
’21	(0.26)	(0.30)	(0.35)	(0.91)	(1.81)
’20	0.26	(0.34)	(0.32)	(0.31)	(0.71)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	9.10	10.40	12.51	5.10	3.60	3.68	1.17	1.04	0.83	0.40	Analyst estimates 2026–2028 Powerpack
	High	20.94	24.67	35.00	19.75	15.44	10.05	4.73	3.02	5.85	4.62
People
People	Employees	80	93	139	160	146	178	118	122	121	69
	Revenue/emp, $m	0.19	0.77	0.43	0.36	0.69	0.21	0.45	0.83	1.14	1.10
Income, $m
Income, $m	Revenue	15	72	60	57	100	37	53	101	138	76
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(59)	(44)	(70)	(103)	(47)	(116)	(99)	3	32	(17)
	EBT margin, %	(391.67)	(60.89)	(118.15)	(178.58)	(46.63)	(310.54)	(186.82)	3.28	23.24	(22.48)
	Net income	(59)	(43)	(85)	(102)	(33)	(116)	(99)	(1)	32	(17)
	Depreciation	3	2	0	0	2	3	2	(5)	(4)	(1)
Per share, $
Per share, $	Revenue	0.42	1.93	1.43	1.27	2.17	0.58	0.81	1.37	1.64	0.55
	Earnings	(1.63)	(1.16)	(2.03)	(2.26)	(0.71)	(1.81)	(1.51)	(0.01)	0.38	(0.15)
	Cash flow	(0.06)	4.58	(1.81)	(3.10)	0.11	(1.86)	(1.69)	(0.76)	(1.02)	(0.55)
	Capex	(0.06)	(0.04)	(0.09)	(0.08)	(0.05)	(0.03)	(0.03)	(0.01)	0.00	0.00
	Free cash flow	(0.11)	4.54	(1.90)	(3.18)	0.06	(1.88)	(1.71)	(0.77)	(1.02)	(0.55)
	Book value	2.17	1.88	3.14	1.13	1.08	(0.01)	(1.30)	(0.64)	(0.01)	0.72
	Shares, m	36	37	42	45	46	64	66	74	84	138
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.71	0.00
	P/S	25.80	11.29	10.57	6.55	3.01	7.44	1.99	1.23	0.63	7.71
	P/B	4.95	11.57	4.81	7.37	6.07	0.00	0.00	0.00	0.00	5.93
	EV/Sales	13.70	6.07	3.24	1.45	(0.11)	(0.64)	(1.57)	(0.45)	(0.07)	5.97
	EV/FCF	(49.60)	2.57	(2.43)	(0.58)	(3.62)	0.20	0.74	0.80	0.11	(6.00)
Cash, $m
Cash, $m	Operating cash flow	(2)	170	(76)	(140)	5	(119)	(111)	(56)	(86)	(76)
	Capex	(2)	(2)	(4)	(3)	(2)	(2)	(2)	(1)	0	0
	Free cash flow	(4)	169	(79)	(144)	3	(121)	(113)	(57)	(87)	(76)
Balance, $m
Balance, $m	Working capital	152	327	348	218	223	232	84	27	22	97
	Total debt	—	—	—	3	3	4	4	5	—	—
	Net debt	(182)	(374)	(436)	(293)	(313)	(302)	(190)	(175)	(101)	(137)
	Shareholders’ equity	78	70	131	51	50	0	(86)	(47)	0	99
Returns, %
Returns, %	ROA	(29.72)	(14.44)	(19.80)	(25.61)	(9.40)	(33.20)	(33.09)	(0.25)	19.77	(14.97)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(57.59)	(58.09)	(84.28)	(112.35)	(65.17)	(469.64)	230.41	0.85	(133.06)	(41.34)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
VECT VectivBio Holding AG	$545.5M	— (loss-making)	— (loss-making)	—	n/m	—	91.93%	0.00%	Compare
PBYI Puma Biotechnology, Inc.	$543.0M	18.2×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
DRUG Bright Minds Biosciences Inc.	$534.7M	— (loss-making)	—	—	n/m	−124.63% (below 0%: shrinking)	0.00%	0.00%	Compare
FTH Faeth Therapeutics, Inc.	$532.3M	— (loss-making)	—	—	n/m	−174.24% (below 0%: shrinking)	0.00%	0.00%	Compare
CTMX CytomX Therapeutics, Inc.	$525.1M	— (loss-making)	— (loss-making)	−92.40% (below 0%: shrinking)	n/m	−14.50% (below 0%: shrinking)	100.00%	(1,677.08%)
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR	$524.8M	— (loss-making)	— (loss-making)	−7.53% (below 0%: shrinking)	n/m	−31.52% (below 0%: shrinking)	0.00%	0.00%	Compare
ACRS Aclaris Therapeutics, Inc.	$513.7M	— (loss-making)	— (loss-making)	−8.33% (below 0%: shrinking)	n/m	−98.77% (below 0%: shrinking)	10.80%	(1,487.91%)	Compare
Median of peers	$538.9M	—	—	−8.33%	—	−88.45%	13.05%	0.00%

All 614 Biotechnology stocks →

CytomX Therapeutics, Inc. (CTMX) key facts

Concern: CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024.
CytomX Therapeutics, Inc. (CTMX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CTMX traded at $2.27, a market capitalization of $525.1 million.
Return on equity was −41.3% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.92 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.